ReviewJournal of industrial microbiology & biotechnology2006
From natural products discovery to commercialization: a success story.
Review in Journal of industrial microbiology & biotechnology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Cell walls of filamentous fungi - challenges and opportunities for biotechnology.Applied microbiology and biotechnology · 2025Review
- Genomic factors shape carbon and nitrogen metabolic niche breadth across Saccharomycotina yeasts.Science (New York, N.Y.) · 2024Article
- Paralemnalia thyrsoides-associated fungi: phylogenetic diversity, cytotoxic potential, metabolomic profiling and docking analysis.BMC microbiology · 2023Article
- Synthesis of Metabolites and Metabolite-like Compounds Using Biocatalytic Systems.Metabolites · 2023Review
- Antibacterial and Anti-Biofilm Activity of Pyrones from aAntibiotics (Basel, Switzerland) · 2022Article
- Kayadiol exerted anticancer effects through p53-mediated ferroptosis in NKTCL cells.BMC cancer · 2022Article
- Professor Arnold L. (Arny) Demain's historical position in the rise of industrial microbiology and biotechnology.Journal of industrial microbiology & biotechnology · 2021Article
- Submerged fermentation of Streptomyces uncialis providing a biotechnology platform for uncialamycin biosynthesis, engineering, and production.Journal of industrial microbiology & biotechnology · 2021Article
- Complex natural product production methods and options.Synthetic and systems biotechnology · 2021Review
- Streptomycetes as platform for biotechnological production processes of drugs.Applied microbiology and biotechnology · 2021Review
- Genome-scale determination of 5´ and 3´ boundaries of RNA transcripts in Streptomyces genomes.Scientific data · 2020Article
- Flux Balance Analysis for Media Optimization and Genetic Targets to Improve Heterologous Siderophore Production.iScience · 2020Article
- Inducible Antibacterial Activity in the Bacillales by Triphenyl Tetrazolium Chloride.Scientific reports · 2020Article
- Improved tolerance of Escherichia coli to oxidative stress by expressing putative response regulator homologs from Antarctic bacteria.Journal of microbiology (Seoul, Korea) · 2020Article
- Mzabimycins A and B, novel intracellular angucycline antibiotics produced bySaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2019Article
- An Aminoglycoside Antibacterial Substance, S-137-R, Produced by Newly Isolated Bacillus velezensis Strain RP137 from the Persian Gulf.Current microbiology · 2019Article
- EngineeringPeerJ · 2019Article
- Metabolic engineering of a carbapenem antibiotic synthesis pathway in Escherichia coli.Nature chemical biology · 2018Article
- Structure elucidation and in silico docking studies of a novel furopyrimidine antibiotics synthesized by endolithic bacterium Actinomadura sp. AL2.World journal of microbiology & biotechnology · 2017Article
- Engineering microbial hosts for production of bacterial natural products.Natural product reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order for a natural product to become a commercial reality, laboratory improvement of its production process is a necessity since titers produced by wild strains could never compete with the power of synthetic chemistry. Strain improvement by mutagenesis has been a major success. It has mainly been carried out by "brute force" screening or selection, but modern genetic technologies have entered the scene in recent years. For every new strain developed genetically, there is further opportunity to raise titers by medium modifications. Of major interest has been the nutritional control by induction, as well as inhibition and repression by sources of carbon, nitrogen, phosphate and end products. Both strain improvement and nutritional modification contribute to the new process, which is then scaled up by biochemical engineers into pilot scale and later into factory size fermentors.
Indexed as
Identifiers
16402247What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.